MRK241227P140000
- 0.00
- 0.000.00%
Merck & Co Newsroom
CICC: Maintains HANSOH PHARMA "Outperform Industry" rating with a Target Price of HKD 21.12.
CICC released a research report stating that it maintains a "outperform the Industry" rating for HANSOH PHARMA (03692), being Bullish on the company's future progress in going global, and maintains a Target Price of HKD 21.12. Due to the possibility that the initial payment for this authorized cooperation may be confirmed in 2025, the bank has lowered its expectations for 2024 authorized revenue and maintained its expectations for 2025 authorized fees, thus reducing the 2024 profit forecast by 9.7% to 4.04 billion yuan while keeping the 2025 profit forecast unchanged. On December 18, 2024, the company announced the granting of a global exclusive license agreement for Merck's HS-10535 (oral GLP-1 receptor agonist). CICC
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
Boeing and 6 More Contrarian Stocks for 2025
Market Chatter: Merck to Discontinue Zinplava for Clostridioides Difficile Infection
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025 -- Barrons.com
Express News | Merck & Co. will cease production of the medication for treating bacterial infections.
Express News | US FDA Says Merck's Zinplava, Injection, 25 Mg/1 Ml to Be Discontinued on Jan 31, 2025 - Website
Dow Rallies 117 Points On Gains For NVIDIA Corp., UnitedHealth Stocks
U.S. stock market in the morning | All three major Indexes turned to decline, with the Dow down 0.7%; some Growth Tech stocks rose, AMD surged over 4%, Broadcom increased nearly 4%, and Apple hit a new high during the session; the Cryptos Concept stocks c
On the evening of the 23rd in Peking time, US stocks opened mixed on Monday. The market is preparing for a shortened trading week due to holidays, and trading is expected to be relatively light this week.
2024's 'Biggest Loses' That Could See Reversal in 2025
BMO Capital has lowered the Target Price for Merck to 105 dollars.
On December 23, Gelonghui reported that BMO Capital downgraded Merck & Co.'s rating from "outperform" to "market perform," and the Target Price was lowered from $136 to $105. (Gelonghui)
Merck will invest over 70 million euros to establish an advanced materials center in Japan.
On December 23, Gelonghui reported that Merck today announced it will invest over 70 million euros to build a new Advanced Materials Development Center at the Shizuoka plant in Japan, expected to be operational by 2026. Including the investments made in the Shizuoka plant since 2021, the total investment has exceeded 0.12 billion euros. The center covers an area of 5,500 square meters and is equipped with the most advanced clean rooms and laboratories, designed for high scalability in preparation for future capacity increases to meet the rapidly growing market.
How to find the "alpha" market in U.S. stocks next year? Goldman Sachs provides an investment guide.
Zhihui Finance has learned that Goldman Sachs analysts said in a report that over the next six months, the materials, Software, and services industries in the USA are most likely to outperform the Large Cap. Goldman Sachs strategist David Kostin stated in a report on December 20 that they introduced a model for USA Stocks to select industries expected to exceed the benchmark Index by 5 percentage points or more, "to identify 'high conviction' views with significant Alpha potential." He noted, "Our model incorporates macro, fundamental, and valuation data as independent variables. We run probability models separately for each Industry, only including
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Musk causes a commotion at Capitol Hill, is a "Trump 2.0" prototype emerging?
Analysis suggests that Musk's recent act of detonating a political nuclear bomb may be a rehearsal for the Trump 2.0 era of Musk's action model, intended to exert pressure on Congress. However, some also say that the consensus at Mar-a-Lago is that Musk has proven to be an effective Weapon to pressure Congress and a scapegoat for any backlash.
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
BMO Capital Downgrades Merck & Co(MRK.US) to Hold Rating, Cuts Target Price to $105
Merck Downgraded by BMO Over Keytruda Concerns